LINEBURG


<< . .

 24
( 30)



. . >>

Belver J, Munoz EA, Ballesteros A et al. (2003). Intravenous albumin does not prevent
moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients:
a randomized controlled study. Hum Reprod 18:2283“8.
Benadiva CA, Davis O, Kligman I et al. (1997). Withholding gonadotropin administration
is an effective alternative for the prevention of ovarian hyperstimulation syndrome.
Fertil Steril 67:724“7.
Ben-Chetrit A, Eldar-Geva T & Gal M (2001). The questionable use of albumin for
the prevention of ovarian hyperstimulation syndrome in an IVF programme:
a randomized placebo-controlled trial. Hum Reprod 16:1880“4.
Ben-Nun I, Shulman A, Ghetler Y et al. (1993). The signi¬cance of 17 beta estradiol levels
in highly responding women during ovulation induction in IVF treatment: its impact
187
REFERENCES




and prognostic value with respect to oocyte maturation and treatment outcome.
J Assist Reprod Genet 10:213“15.
Ben-Rafael Z, Orvieto R, Dekel A et al. (1995). Intravenous albumin and the prevention of
severe ovarian hyperstimulation syndrome [comment]. Hum Reprod 10:2750“2.
Blankstein J, Shalev J, Saadon T et al. (1987). Ovarian hyperstimulation syndrome
prediction by number and size of preovulatory follicles. Fertil Steril 47:597“602.
Bracero MW, Jurema MN, Posada JG et al. (2001). Triggering ovulation with leuprorelide
acetate (LA) instead of human chorionic gonadotrophin (hCG) after the use of
ganirelix for in-vitro fertilization-embryo transfer (IVF-ET) does not compromise
cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertil Steril
S-93, Abstract O-245. American Society for Reproductive Medicine 57th Annual
Meeting, Orlando, FL, General Program Prize, Abstracts of the scienti¬c oral and
poster sessions program supplement.
Buvat J, Buvat-Herbaut M, Marcolin G et al. (1989). Puri¬ed follicle stimulating hormone
in polycystic ovary syndrome: slow administration is safer and more effective. Fertil
Steril 51:553“9.
Cha K, Koo JJ, Choi DH et al. (1991). Pregnancy after in vitro fertilitzation of human
follicular oocytes collected from non stimulated cycles, their culture in vitro and their
transfer in a donor oocyte program. Fertil Steril 55:103“20.
Cha KY & Chian RC (1998). Maturation in vitro of immature human oocytes for clinical
use. Hum Reprod Update 4:103“20.
Cha KY, Han SY, Chung HM et al. (2000). Pregnancies and deliveries after in vitro
maturation culture followed by in vitro fertilization and embryo transfer without
stimulation in women with polycystic ovary syndrome. Fertil Steril 73:978“83.
Chang P, Kenley S, Burns T et al. (2001). Recombinant human chorionic gonadotrophin
(rhCG) in assisted reproductive technology: results of a clinical trial comparing
two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of ¬nal follicular
maturation in in vitro fertilization embryo transfer. Fertil Steril 76:67“74.
Chang RJ (2004). Polycystic ovary syndrome and hyperandrogenic states. In (Strauss,
Barbieri, Eds),Yen and Jaffe™s Reproductive Endocrinology: Pathophysiology and Clinical
Management, 5th edition. Philadelphia: Elsevier & Saunders, Chapter 19, p. 600.
Chen CD, Wu MY, Yang JH et al. (1997). Intravenous albumin does not prevent the
development of severe ovarian hypertimulation syndrome. Fertil Steril 68:287“91.
Chian RC & Tan SL (2002). Maturational and developmental competence of cululus-free
immature human oocytes derived from stimulated and intracytoplasmic sperm
infection cycles. Reprod Biomed Online 5:125“32.
Chian RC, Buckett WM, Too LL et al. (1999a). Pregnancies resulting from in vitro
matured oocytes retrieved from patients with polycystic ovary syndrome after
priming with human chorionic gonadotropin. Fertil Steril 72:639“42.
Chian RC, Gulekli B, Buckett WM et al. (1999b). Priming with human chorionic
gonadotropin before retrieval of immature oocytes in women with infertility due to
the polycystic ovary syndrome. New Eng J Med 341:1624“6.
Chian RC, Buckett WM, Tulandi T et al. (2000). Prospective randomized study
of human chorionic gonadotrophin priming before immature oocyte retrieval from
unstimulated women with polycystic ovarian syndrome. Hum Reprod 15:165“70.
Chian RC, Gulekli B, Buckett WM et al. (2001). Pregnancy and delivery after
cryopreservation of zygotes produced by in-vitro matured oocytes retrieved from
a woman with polycystic ovarian syndrome. Hum Reprod 16:1700“2.
Child TJ, Abdul-Jalil AK, Gulekli B et al. (2000). In vitro maturation and fertilization
of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with
polycystic ovary syndrome. Fertil Steril 76:936“42.
Child TJ, Phillips SJ, Abdul-Jalil AK et al. (2002). A comparison of in vitro matura-
tion and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol
100:665“70.
188 PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME




Christin-Maitre S & Hughes JN (2003). A comparative randomized multicentric study
comparing the step-up versus the step-down protocol in polycystic ovary syndrome.
Hum Reprod 18:1626“31.
Costabile L, Unfer V, Manna C et al. (2000). Use of intramuscular progesterone versus
intravenous albumin for the prevention of ovarian hyperstimulation syndrome.
Gynecol Obstet Invest 50:182“5.
D™Angelo A & Amso N (2002a). ˜Coasting™ (withholding gonadotrophins) for preventing
ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 3:CD002811.
D™Angelo A & Amso NN (2002b). Embryo freezing for preventing ovarian hyperstimula-
tion syndrome: a Cochrane review. Hum Reprod 17:2787“94.
Daniell JF & Miller W (1989). Polycystic ovaries treated by laparoscopic laser vaporization.
Fertil Steril 51:232“6.
Dechaud H, Anahory T, Aligier N et al. (2000). Coasting: a response to excessive ovarian
stimulation. Gynecol Obstet Fertil 28:115“19.
DeJonge D, Macklon NS & Mannaerts BMJ et al. (1998). High dose gonadotrophin-
releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation
syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod
13:573“5.
De Leo V, la Marca A, Ditto A et al. (1999). Effects of metformin on gonadotrophin-
induced ovulation in women with polycystic ovary syndrome. Fertil Steril 72:282“5.
Delvigne A (2004). Epidemiology and pathophysiology of ovarian hyperstimulation
syndrome. In (Gerris J, Olivennes F, de Sutter P, Eds), Assisted Reproductive
Technologies: Quality and Safety, New York: Parthenon Publishing, Chapter 12,
pp. 149“62.
Delvigne A & Rozenberg S (2001). Preventive attitude of physicians to avoid OHSS in IVF
patients. Hum Reprod 16:2491“5.
Delvigne A & Rozenberg S (2002a). A qualitative systematic review of coasting,
a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum
Reprod Update 8:291“6.
Delvigne A & Rozenberg S (2002b). Epidemiology and prevention of ovarian
hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8:559“77.
Delvigne A, Demoulin A, Smitz J et al. (1993). The ovarian hyperstimulation syndrome in
in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.
Hum Reprod 8:1353“60.
Delvigne A, Carlier C & Rozenberg S (2001). Is coasting effective for preventing ovarian
hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone
antagonist during an in vitro fertilization cycle? Fertil Steril 76:844“6.
Delvigne A, Manigart Y, Kostyla et al. (2002). Oocyte quality after coasting for
ovarian hyperstimulation syndrome prevention. Hum Reprod. 17 (Abstract book 1,
p. 450):153.
Dhont M, Van der straiten F, De Sutter P (1998). Prevention of severe ovarian
hyperstimulation by coasting. Fertil Steril 70:847“50.
Donderwinkel PF, Schoot DC, Pache TD et al. (1993). Luteal function following ovulation
induction in polycystic ovary syndrome patients using exogenous gonadotrophins in
combination with a gonadotrophin-releasing hormone agonist. Human Reprod
8:2027“32.
Driscoll GL, Tyler JP, Hangan JT et al. (2000). A prospective, randomized, controlled,
double-blind, double-dummy comparison of recombinant and urinary HCG for
inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum
Reprod 15:1305“10.
Edwards R (1965). Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and
human ovarian oocytes. Nature 20:349“51.
Edwards R, Bavister B & Steptoe P (1969). Early stages of fertilization in vitro of human
oocytes matured in vitro. Nature 221:632“5.
189
REFERENCES




Egbase PE, Makhseed M, Al Sharhan M et al. (1997). Timed unilateral ovarian follicular
aspiration prior to administration of human chorionic gonadotrophin for the
prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization:
a prospective randomized study. Hum Reprod 12:2603“6.
Egbase P, Al-Awadi S, Al-sharhan M et al. (1998). Unilateral ovarian diathermy prior to
successful in-vitro fertilisation: a strategy to prevent ovarian hyperstimulation
syndrome? J Obstet Gynaecol 18:171“3.
Egbase PE, Sharhan MA & Grudzinskas JG (1999). Early unilateral follicular aspiration
compared with coasting for the prevention of severe ovarian hyperstimulation
syndrome: a prospective randomized study. Hum Reprod 14:1421“5.
Egbase PE, Al-Sharhan M & Grudzinskas JG (2002). Early coasting in patients with
polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod
17:1212“16.
El-Sheikh MM, Hussein M, Fouad S et al. (2001). Limited ovarian stimulation (LOS)
prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in
polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 94:245“9.
Emperaire JC (2005). Triggering ovulation with LH. Reprod Biomed Online 11:270.
Emperaire JC & Ruf¬e A (1991). Triggering ovulation with endogenous
luteinizing hormone may prevent ovarian hyperstimulation syndrome. Hum
Reprod 6:506“10.
Emperaire JC & Edwards RG (2004). Time to revolutionize the triggering of ovulation.
Reprod Biomed Online 9:480“3.
Endo T, Honnma H, Hayashi T et al. (2002). Continuation of GnRH agonist administration
for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome follow-
ing elective cryopreservation of all pronucleate embryos. Hum Reprod 17:2548“51.
European Orgalutran Study Group (2000). Treatment with the gonadotrophin-releasing
hormone antagonist ganirelix in women undergoing ovarian stimulation with
recombinant follicle stimulation hormone is effective, safe and convenient: results of
a controlled, randomized, multicenter trial. Hum Reprod 15:1490“98.
European Recombinant LH Study Group (2001). Recombinant human leuteinizing
hormone is as effective as, but safer than, urinary human chorionic gonadotrophin in
inducing ¬nal follicular maturation and ovulation in in-vitro fertilization procedures:
results of a multi-center double blind study. J Clin Endocrinol 86:2607“16.
European-Middle East Orgalutran Study Group (2001). Comparable clinical outcome
using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist
triptorelin for the prevention of premature LH surges in women undergoing ovarian
stimulation. Hum Reprod 16:644“51.
The European Recombinant Human Chorionic Gonadotropin Study Group (2000).
Induction of ¬nal follicular maturation and early luteinization in women undergoing
superovulation for ART“recombinant human chorionic gonadotropin (rhCG;
Ovidrel) versus urinary hCG (Profasi). Hum Reprod 15:1446“51.
Farquhar C, Vandederckhove P & Lilford R (2001). Laparoscopic ˜˜drilling™™ by diathermy
or laser for ovulation induction in anovulatroy polycystic ovary syndrome. Cochrane
Database Syst Rev 4:CD001122.
Fatemi HM, Platteau P, Albano C et al. (2002). Rescue IVF and coasting with the use of
a GnRH antagonist after ovulation induction. Reprod Biomed Online 5:273“5.
Fauser B & Macklon N (2004). Medical approaches to ovarian stimulation for infertility.
In (Strauss, Barbieri, Eds), Reproductive Endocrinology: Physiology, Pathophysiology and
Clinical Management, 5th edition. Philadelphia: Elsevier, Chapter 31, pp. 965“1012.
Felberbaum RE & Diedrich K (2003). Gonadotrophin-releasing hormone antagonists:
will they replace the agonists? Reprod Biomed Online 6:43“53.
Felberbaum RE, Reissmann T, Kupker W et al. (1995). Preserved pituitary response under
ovarian stimulation with hMG and GnRH antagonists (Cetrorelix) in women with
tubal infertility. Eur J Obstet Gynecol Reprod Biol 61:151“5.
190 PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME




Ferraretti AP, Gianaroli L, Magli C et al. (1999). Elective cryopreservation of all
pronucleate embryos in women at risk of ovarian hyperstimulation syndrome:
ef¬ciency and safety. Hum Reprod 14:1457“60.
Ferraretti AP, Gianaroli L, Magli C et al. (2001). Transvaginal ovarian drilling: a
new surgical treatment for improving the clinical outcome of assisted reproductive
technologies in patients with polycystic ovary syndrome. Fertil Steril 76:812“46.
Feste JR (1990). General aspects of CO2 laser laparoscopy. In (Baggish MS, Ed.),
Endoscopic Laser Surgery, New York: Elsevier, pp. 67“8.
Fluker MR, Hooper WM & Yuzpe AA (1999). Withholding gonadotrophins (˜coasting™) to
minimize the risk of ovarian hyperstimulation during superovulation and in-vitro
fertilization-embryo transfer cycles. Fertil Steril 71:294“301.
Fluker M, Grifo J, Leader A et al. (2001). Ef¬cacy and safety of ganirelix acetate versus
leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fertil Steril 75:38“45.
Forman RG, Frydman R, Egan D et al. (1990). Severe ovarian hyperstimulation syndrome
using agonists of gonadotropin-releasing hormone for in vitro fertilization:
a European series and a proposal for prevention. Fertil Steril 53:503“9.
Fountain S, Rizk B, Avery S et al. (1995). An evaluation of the effect of pentoxifylline on
sperm function and treatment outcome of male-factor infertility: a preliminary study.
J Assist Reprod Genet 12:704“9.
Friedman CI, Schmidt GE, Chang FE et al. (1984). Severe ovarian hyperstimulation
syndrome following follicular aspiration. Am J Obstet Gynecol 150:436“7.
Friedman CI, Seifer DB, Kennard EA et al. (1998). Elevated level of follicular ¬‚uid vascular
endothelial growth factor is a marker of diminished pregnancy potential. Fertil Steril
64:268“72.
Fukaya T, Murakami T, Tamura M et al. (1995). Laser vaporization of the ovarian surface
in polycystic ovary disease results in reduced ovarian hyperstimulation and improved
pregnancy rates. Am J Obstet Gynecol 173:119“25.
Garcia-Velasco JA, Zuniga A & Pacheco A (2004). Coasting acts through downregulation
of VEGF gene expression and protein secretion. Hum Reprod 19:1530“8.
Gerris J & Van Royen E (2000). Avoiding multiple pregnancies in ART: a plea for single
embryo transfer. Hum Reprod 15:1884“8.
Gerris J, De Vits A, Joostens M et al. (1995). Triggering of ovulation in human
menopausal gonadotrophin-stimulated cycles: comparison between intravenously
administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH
agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000
IU). Hum Reprod 10:56“62.
Gerris J, de Neubourg D, Van Royen E et al. (2002). Elective single day 3 embryo
transfer halves the twinning rate without decrease in the ongoing pregnancy rate of an
IVF/ICSI program. Hum Reprod 17:2626“31.
Gerris J, de Sutter P, de Neuberg D et al. (2004). A real-life prospective health economic
study of elective single embryo transfer versus two-embryo transfer in ¬rst IVF/ICSI
cycles. Hum Reprod 19:917“23.
¨
Gjonnaess H (1984). Polycystic ovarian syndrome treated by ovarian electrocautery
through the laparoscope. Fertil Steril 41:20“5.
¨
Gjonnaess H (1994). Ovarian electrocautery in the treatment of women with the polycystic
ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scan
73:407“12.
¨
Gjonnaess H & Norman N (1987). Endocrine effects of ovarian electrocautery in patients
with polycystic ovarian disease. Br J Obstet Gynaecol 94:779“82.
Goldberg JM & Falcone T, Eds (2000). Atlas of Endoscopic Techniques in Gynecology,
Edinburgh: W. B. Saunders, Chapter 13, p. 61.
Gokman O, Ugur M, Ekin M et al. (2001). Intravenous albumin versus hydroxyethyl
starch for the prevention of ovarian hyperstimulation in an in-vitro fertilisation
191
REFERENCES




programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol
Reprod Biol 96:187“92.
Gomez R, Simon G, Remohi J et al. (2001). Vascular endothelial growth factor 121 and
164 isoforms increase vascular permeability in hyperstimulation rats. Fertil Steril
76(Suppl 3):4339“48.
Gomez R, Lima I, Simon C et al. (2004). Administration of low-dose LH induces
ovulation and prevents vascular hyperpermeability and vascular endothelial growth
factor expression in superovulated rats. Reproduction 127:483“9.
Gonen Y, Balakier H, Powell W et al. (1990). Use of gonadotrophin-releasing hormone
agonist to trigger follicular maturation for in-vitro fertilization. J Clin Endocrinol
Metab 71:918“22.
Grace J, Rizk B, Mulekar M (2005). Coasting decreases ovarian hyperstimulatin syndrome
in patients at risk. Is the quality of oocytes, embryos and pregnancy rate the price to
pay? Fertil Steril 84(Suppl I)s300: 416.
Graf MA, Fischer R, Naether OG et al. (1997). Reduced incidence of ovarian
hyperstimulation syndrome by prophylactic infusion of hydroxyethyl starch solution
in an in-vitro fertilization programme. Hum Reprod 12:2599“602.
Grochowski D, Wolczynski S, Kuczynski W et al. (2001). Correctly timed coasting reduces
the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an
in vitro fertilization program. Gynecol Endocrinol 15:234“8.
Gurgan T, Urman B, Aksu T et al. (1992). The effect of short-interval laparoscopic lysis of
adhesions on pregnancy rates following Nd-Yag laser photocoagulation of polycystic
ovaries. Obstet Gynecol 30:45“7.
Halme J, Toma SK & Talbert LM (1995). A case of severe ovarian hyperstimulation in a
healthy oocyte donor. Fertil Steril 64:857“9.
Hamilton-Fairley D, Kiddy D, Watson H et al. (1991). Low-dose gonadotrophin therapy
for induction of ovulation in 100 women with polycystic ovary syndrome.
Hum Reprod 6:1095“9.
Haning RV Jr, Austin CW, Carlson IH et al. (1983). Plasma estradiol is superior to
ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation
during induction of ovulation with menotropins. Fertil Steril 40:31“6.
Hedon B, Hughes JN, Emperaire JC et al. (1998). A comparative prospective study of
a chronic low dose versus a conventional ovulation stimulation regimen using
recombinant human follicle stimulating hormone in anovulatory women. Hum
Reprod 13:2688“92.
Heylen SM, Puttemans PJ & Brosens IA (1994). Polycystic ovarian disease treated by
laparoscopic argon laser capsule drilling: comparison of vaporization versus
perforation technique. Hum Reprod 9:1038“42.
Hoeger KM, Kochman L, Wixom N et al. (2004). A randomized, 48-week, placebo-
controlled trial of intensive lifestyle modi¬cation and/or metformin therapy in over-
weight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82:421“9.
Homburg R, Armar NA, Eshel J et al. (1988). In¬‚uence of serum luteinizing hormone
concentrations on ovulation, conception and early pregnancy loss in polycystic ovary
syndrome. Br Med J 297:1024“6.
Homburg R, Levy T & Ben-Rafael Z (1995). A comparative prospective study of
conventional regimen with chronic low-dose administration of follicle-stimulating
hormone in polycystic ovary syndrome: slow administration is safer and more
effective. Fertil Steril 63:729“33.
Hornnes P, Giroud D, Howles C et al. (1993). Recombinant human follicle-stimulating
hormone treatment leads to normal follicular growth, estradiol secretion, and
pregnancy in a World Health Organization group II anovulatory woman. Fertil Steril
60:724“6.
Howles CM (2002). The place of gonadotrophin-releasing hormone antagonists in
reproductive medicine. Reprod Biomed Online 4(Suppl 3):64“71.
192 PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME




Humaidan O, Bredkjaer HE, Bungum I et al. (2005). GnRH agonist (buserelin) or hCG for
ovualtion induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized
study. Hum Reprod 20:1213“20.
Imoedemhe DAG, Chan RCW, Signe AB et al. (1991). A new approach to the
management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization
program. Hum Reprod 6:1088“91.
International Recombinant Human Chorionic Gonadotropin Study Group (2001).
Induction of ovulation in World Health Organization group II anovulatory women
undergoing follicular stimulation with recombinant human follicle-stimulating
hormone: a comparison of recombinant human chorionic gonadotropin (rhCG)
and urinary hCG. Fertil Steril 75:1111“18.
Isaza V, Garcia-Velasco JA, Aragones M et al. (2002). Oocyte and embryo quality after
coasting: the experience from oocyte donation. Hum Reprod 17:1737“58.
Isik AZ & Vicdan K (2001). Combined approach as an effective method in the prevention
of severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol
97:208“12.
Isik AZ, Gokmen A, Zeyneloglu HB et al. (1996). Intravenous albumin prevents moderate-
severe ovarian hyperstimulation in in vitro fertilisation patients: a prospective
randomized and controlled study. Eur J Obstet Gynecol Reprod Biol 70:170“83.
Itskovitz J, Boldes R, Levron J et al. (1991). Induction of pre-ovulatory luteinizing
hormone surge and prevention of hyperstimulation syndrome by gonadotrophin-
releasing hormone agonist. Fertil Steril 56:213“20.
Itskovitz-Eldor J, Kol S & Mannaerts B (2000). Use of a single bolus of GnRH agonist
triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women
undergoing ovarian stimulation for assisted reproduction, with special reference to
the prevention of ovarian hyperstimulation syndrome: preliminary report: short
communication. Hum Reprod 15:1965“8.
Jewelewicz R, James SL, Finster M et al. (1972). Quintuplet gestation after ovulation
induction with menopausal gonadotropins and pituitary luteinizing hormone. Obstet
Gynecol 40:1“5.
Keckstein J, Rossmanith W, Spatzier K et al. (1990). The effect of laparoscopic treatment
of polycystic ovarian disease by CO2 laser or Nd:YAG laser. Surg Endoscopy 4:103“7.
Kinget K, Nijs M, Cox AM et al. (2002). A novel approach for patients at risk for ovarian
hyperstimulation syndrome: elective transfer of a single zona free blastocyst on day 5.
Reprod Biomed Online 4:51“5.
Koike T, Araki S, Ogawa S et al. (1999). Does i.v. albumin prevent ovarian
hyperstimulation syndrome? Hum Reprod 14:1920.
Kolibianakis EM, Schultze-Morgan A, Schroer A et al. (2005). A lower ongoing pregnancy
rate can be expected when GnRH agonist is used for triggering ¬nal oocyte
maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Hum Reprod 20:2887“92.
Konig E, Bussen S, Sitterlin M & Steck T (1998). Prophylactic intravenous hydroxyethyl
starch solution prevents moderate“severe ovarian hyperstimulation in in-vitro
fertilization patients: a prospective, randomized, double-blind and placebo-
controlled study. Hum Reprod 13:2421“4.
Kovacs GT (1998). Polycystic ovaries, surgical management. In (Sutton C, Diamond M,
Eds), Endoscopic Surgery for Gynecologists, London: W.B. Saunders, Chapter 23,
pp. 233“40.
Kovacs G, Buckler H, Bangah M et al. (1991). Treatment of anovulation due to
polycystic ovarian syndrome by laparoscopic ovarian electrocautery. Br J Obstet
Gynecol 98:30“5.
Kulikowski M, Wolczynski S, Kuczynski W et al. (1995). Use of GnRH analog for
induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian
hyperstimulation syndrome. Gynecol Endocrinol 9:97“9.
193
REFERENCES




Kyono K, Fukunaga N, Haigo K et al. (2002). Successful delivery following
cryopreservation of zygotes produced by in vitro matured oocytes retrieved from
a woman with polycystic ovarian syndrome-like disease: a case report. J Assisted
Reprod Genetics 19:390“3.
Lainas T, Petsas G, Stavropoulou G et al. (2002). Administration of methylprednisolone to
prevent severe ovarian hyperstimulation syndrome in patients undergoing in-vitro
fertilization. Fertil Steril 78:529“33.
Lanzone A, Fulghesu AM, Apa R et al. (1989). LH surge induction by GnRH agonist
at the time of ovulation. Gynecol Endocrinol 3:213“15.
Le Du A, Kadoch IJ, Bourcigaux N et al. (2005). In vitro oocyte maturation for the
treatment of infertility associated with polycystic ovarian syndrome: the French
experience. Hum Reprod 20:420“4.
Lee C, Tummon I, Martin J et al. (1998). Does withholding gonadotrophin administration
prevent severe ovarian hyperstimulation syndrome? Hum Reprod 13:1157“8.
Levinsohn-Tavor S, Friedler M, Schachter A et al. (2003). Coasting “ what is the best
formula? Hum Reprod 18:937“40.
Lewit N, Kol S, Manor D et al. (1995). The use of GnRH analogues for induction of
the pre-ovulatory gonadotrophin surge in assisted reproduction and prevention
of the ovarian hyperstimulation syndrome. Gynecol Endocrinol 4(Suppl):13.
Lewit N, Kol S, Ronene N et al. (1996). Does intravenous administration of human
albumin prevent severe ovarian hyperstimulation syndrome? Fertil Steril 66:654“6.
Liu J, Lu G, Qian Y et al. (2003). Pregnancies and births achieved from in vitro matured
oocytes retrieved from poor responders undergoing stimulation in in vitro

<< . .

 24
( 30)



. . >>

Copyright Design by: Sunlight webdesign